BRPI0414443A - imunógenos consensuais/ancestrais - Google Patents

imunógenos consensuais/ancestrais

Info

Publication number
BRPI0414443A
BRPI0414443A BRPI0414443-0A BRPI0414443A BRPI0414443A BR PI0414443 A BRPI0414443 A BR PI0414443A BR PI0414443 A BRPI0414443 A BR PI0414443A BR PI0414443 A BRPI0414443 A BR PI0414443A
Authority
BR
Brazil
Prior art keywords
immunogen
consensual
immunogens
inducing
immune response
Prior art date
Application number
BRPI0414443-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Bette T Korber
Beatrice H Hahn
George M Shaw
Denise Kothe
Ying Ying Li
Julie Decker
Original Assignee
Univ Duke
Univ Alabama Res Found
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Univ Alabama Res Found, Univ California filed Critical Univ Duke
Publication of BRPI0414443A publication Critical patent/BRPI0414443A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0414443-0A 2003-09-17 2004-09-17 imunógenos consensuais/ancestrais BRPI0414443A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60472204P 2004-08-27 2004-08-27
PCT/US2004/030397 WO2005028625A2 (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Publications (1)

Publication Number Publication Date
BRPI0414443A true BRPI0414443A (pt) 2006-11-21

Family

ID=34381074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414443-0A BRPI0414443A (pt) 2003-09-17 2004-09-17 imunógenos consensuais/ancestrais

Country Status (10)

Country Link
US (3) US8071107B2 (enExample)
EP (2) EP1667714B1 (enExample)
JP (3) JP4773352B2 (enExample)
KR (2) KR20120086379A (enExample)
CN (2) CN1852734B (enExample)
AU (1) AU2004274937B9 (enExample)
BR (1) BRPI0414443A (enExample)
CA (2) CA2918585C (enExample)
IL (3) IL174380A0 (enExample)
WO (1) WO2005028625A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
CN1505528A (zh) 2000-09-22 2004-06-16 �ſ���ѧ��˾ 包含结合hiv包膜蛋白的配体的免疫原
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
BRPI0414443A (pt) 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
EP1800126B1 (en) 2004-09-08 2014-12-17 The United States of America as represented by the Secretary of Health and Human Services, NIH Compositions and methods for the detection of hiv-1/hiv-2 infection
AU2006283101B2 (en) * 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
US7951377B2 (en) 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
PL2392587T3 (pl) * 2006-03-10 2016-08-31 Peptcell Ltd Sekwencje i kompozycje peptydów
ES2388443T3 (es) * 2006-03-29 2012-10-15 Dana-Farber Cancer Institute, Inc. Métodos y composiciones para inducir una respuesta inmune frente a VIH y modelos para ensayo
DK2029168T3 (da) * 2006-06-02 2013-01-14 Int Aids Vaccine Initiative HIV-1 Clade A konsensussekvenser, antigener og transgener.
CA3184778A1 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
WO2008118470A2 (en) * 2007-03-27 2008-10-02 The Regents Of The University Of California Acute transmitted hiv envelope signatures
NZ593598A (en) 2008-11-18 2013-02-22 Beth Israel Hospital Optimized antiviral vaccines with improved cellular immunogenicity
AU2011219025A1 (en) 2010-02-25 2012-09-27 Duke University Method of inducing the production of protective anti-HIV-1 antibodies
EP2542566A4 (en) * 2010-03-03 2013-09-11 Uab Research Foundation MOLECULAR CLONE OF HIV-1
WO2012047267A2 (en) * 2010-09-28 2012-04-12 Duke University Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2820035B1 (en) 2012-03-02 2019-01-09 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
CA2878599A1 (en) * 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
US9675687B2 (en) * 2013-03-15 2017-06-13 University Of Massachusetts Compositions and methods to treat AIDS
JP6769869B2 (ja) * 2013-10-16 2020-10-14 ニユー・イングランド・バイオレイブス・インコーポレイテツド 強化された特性を有する逆転写酵素
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
SG10202001956UA (en) * 2016-09-15 2020-04-29 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US10828363B1 (en) * 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
WO2018067580A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
EP3860650A4 (en) 2018-10-01 2022-06-29 Duke University Hiv-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
EP4499139A2 (en) * 2022-03-31 2025-02-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Immunogens and vaccine compositions against hiv
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
WO2001060838A2 (en) 2000-02-18 2001-08-23 University Of Washington Aids ancestral viruses and vaccines
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CN1505528A (zh) 2000-09-22 2004-06-16 �ſ���ѧ��˾ 包含结合hiv包膜蛋白的配体的免疫原
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
BRPI0414443A (pt) 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Also Published As

Publication number Publication date
AU2004274937B2 (en) 2011-03-24
US20180296665A1 (en) 2018-10-18
CA2539325A1 (en) 2005-03-31
JP6165612B2 (ja) 2017-07-19
CN1852734A (zh) 2006-10-25
JP2007505624A (ja) 2007-03-15
US20120087938A1 (en) 2012-04-12
EP2371387A2 (en) 2011-10-05
IL202249A (en) 2015-08-31
WO2005028625A3 (en) 2005-06-02
EP1667714B1 (en) 2018-01-03
AU2004274937A1 (en) 2005-03-31
HK1097446A1 (en) 2007-06-29
IL174380A0 (en) 2006-08-01
CA2918585A1 (en) 2005-03-31
CA2539325C (en) 2016-03-22
CA2918585C (en) 2019-05-21
EP2371387A3 (en) 2012-01-25
EP1667714A4 (en) 2008-09-24
US10946090B2 (en) 2021-03-16
JP4773352B2 (ja) 2011-09-14
IL230011A0 (en) 2014-01-30
US20070178562A1 (en) 2007-08-02
JP2014079250A (ja) 2014-05-08
JP2011136997A (ja) 2011-07-14
US9844589B2 (en) 2017-12-19
WO2005028625A2 (en) 2005-03-31
AU2004274937B9 (en) 2011-04-14
CN102010463A (zh) 2011-04-13
CN1852734B (zh) 2010-12-01
AU2004274937A2 (en) 2005-03-31
KR20070028291A (ko) 2007-03-12
US8071107B2 (en) 2011-12-06
KR20120086379A (ko) 2012-08-02
EP1667714A2 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
WO2005028625A3 (en) Consensus/ancestral immunogens
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2004007679A3 (en) Dendritic cell pontentiation
BRPI0513390A (pt) vacinas contra aids contendo construções de ácido nucléico cmv/r
DK1673397T3 (da) Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
DK1326961T3 (da) Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
CO5680456A2 (es) Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
NO20072733L (no) Doseformer
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
DK1557462T3 (da) Transplantataccept-inducerende celler af monocytisk oprindelse, deres fremstilling og anvendelse
NO20050917L (no) Thiomolybdatanaloger og anvendelser derav
BR0309963A (pt) Proteìna de fusão das proteìnas reguladoras/acessórias do hiv
TW200517121A (en) Immunogen
DE602004027251D1 (de) Herstellung von 1,3-diphenylprop-2-en-1-onderivaten
ES8708250A1 (es) Un procedimiento para producir glucagon o fragmentos o derivados del mismo en levadura
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2324 DE 21-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.